Author

Claudia P. González-Hunt

Duke UniversityORCID 0000-0002-2736-0001Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:DNA methylation· 2 Research Focus:benchmarking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Laurie H. SandersiD· 3 shared Nicholas PenaiD· 2 shared Tara Richbourg· 2 shared Andrea M. WeinsteiniD· 1 shared Carlos Montes· 1 shared Carolyn G. CheniD· 1 shared Carrolee Barlow· 1 shared Dario R. AlessiiD· 1 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Laurie H. SandersORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Parkinson's disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling

Jennifer Liu, Claudia P. González-Hunt, Tara Richbourg, Ivana Barraza, Carolyn G. Chen, Carlos Montes, Lingyan Ma, Ruihua Cao, Vishruth Hanumaihgari, Natalie R. Gassman, Elise Fouquerel, Laurie H. Sanders

This study shows that the LRRK2 G2019S mutation causes oxidative nuclear DNA damage and PARP1 hyperactivation, leading to cellular vulnerability in Parkinson's disease.

bioRxiv · Mar 1, 2026 · PreprintCell Biology

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage

Nicholas Pena, Tara Richbourg, Claudia P. González-Hunt, Rui Qi, Paul B. Wren, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders

The paper tests a G2019S selective LRRK2 inhibitor, EB-42168, showing it reduces mtDNA damage in G2019S models and patient cells better than a non-selective inhibitor.

npj Parkinson s Disease · Mar 1, 2024Peer-reviewedNeuroscience

A mitochondrial blood-based patient stratification candidate biomarker for Parkinson's disease

Rui Qi, Esther M. Sammler, Claudia P. González-Hunt, Nicholas Pena, Jeremy P. Rouanet, Steven D. Goodson, Marie Fuzatti, Fabio Blandini, Kirk I. Erickson, Andrea M. Weinstein, Shalini Padmanabhan, Fox BioNet (FBN) investigators, Francesca Tonelli, Dario R. Alessi, Sruti Shiva, Laurie H. Sanders

The paper identifies mtDNA damage as a blood-based biomarker for Parkinson's disease, showing increased levels in early-stage patients and mutation carriers, suggesting its potential for patient stratification in clinical trials.

bioRxiv · Feb 7, 2022 · PreprintNeuroscience